| Drug |
Lead
Company |
Phase (sort) |
Indication (sort) |
Est. Approval
Date |
Likelihood of
Approval |
Peak Potential U.S. Revenue
(M) |
| Angiomax
|
The
Medicines Company (MDCO) |
Approved (Clinical
Detail) |
Percutaneous
Coronary Interventions (PCIs) for Stable
Angina |
12/00 |
100% (Same As
Avg.) |
$
98.5 |
| Angiomax
|
The
Medicines Company (MDCO) |
III (Clinical
Detail) |
Coronary Artery
Bypass Graft (CABG) |
10/06 |
72%
(5% Above
Avg.) |
$
39.2 |
| Angiomax
|
The
Medicines Company (MDCO) |
III (Clinical
Detail) |
Peripheral
Arterial Disease |
N/A |
74%
(7% Above
Avg.) |
$
52.6 |
| Angiomax
|
The
Medicines Company (MDCO) |
Approved (Clinical
Detail) |
Acute Coronary
Syndrome (ACS) |
12/00 |
100% (Same As
Avg.) |
$
205.1 |
| Angiomax
|
The
Medicines Company (MDCO) |
III (Clinical
Detail) |
Cardiac Valve
Surgery |
10/06 |
70%
(3% Above
Avg.) |
$
13.4 |
| Argatroban |
Encysive
Pharmaceuticals (ENCY) |
Approved (Clinical
Detail) |
Heparin-Induced
Thrombocytopenia (HIT) |
06/00 |
100% (Same As
Avg.) |
$
238.8 |
| Argatroban |
Encysive
Pharmaceuticals (ENCY) |
Suspended (Clinical
Detail) |
Ischemic
Stroke |
N/A |
N/A |
N/A |
| ATryn |
GTC
Biotherapeutics, Inc. (GTCB) |
III (Clinical
Detail) |
Anticoagulation |
N/A |
67%
(Same As Avg.) |
N/A |
| AZD0837 |
AstraZeneca
PLC (AZN) |
II (Clinical
Detail) |
Venous
Thromboembolism (VTE) |
N/A |
N/A |
N/A |
| Exanta
|
AstraZeneca
PLC (AZN) |
III (Clinical
Detail) |
Venous
Thromboembolism (VTE) |
N/A |
55%
(12% Below
Avg.) |
$
113.3 |
| Exanta
|
AstraZeneca
PLC (AZN) |
Suspended (Clinical
Detail) |
Dysrhythmia
(Arrhythmia) |
N/A |
1%
(1% Above
Avg.) |
$
321.5 |
| Flolan |
GlaxoSmithKline
plc (GSK) |
Approved (Clinical
Detail) |
Pulmonary
Arterial Hypertension (PAH) |
09/95 |
100% (Same As
Avg.) |
N/A |
| Refludan |
Pharmion
Corporation (PHRM) |
Approved in Europe (Clinical
Detail) |
Heparin-Induced
Thrombocytopenia (HIT) |
N/A |
N/A |
N/A |
| rh
Thrombin |
ZymoGenetics,
Inc. (ZGEN) |
II (Clinical
Detail) |
Hemostasis |
N/A |
32%
(2% Above
Avg.) |
N/A |
